| Title: |
Exposure–Response Analyses of Olaparib in Real-Life Patients with Ovarian Cancer. |
| Authors: |
Mohmaed Ali, Ma Ida, Bruin, Maaike A. C., Dezentjé, Vincent O., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D. R. |
| Source: |
Pharmaceutical Research; May2023, Vol. 40 Issue 5, p1239-1247, 9p |
| Subject Terms: |
OVARIAN cancer, CANCER patients, LUTEINIZING hormone releasing hormone, OLAPARIB, PANCREATIC cancer, PROSTATE cancer, WATCHFUL waiting |
| Abstract: |
Background: Olaparib is given in a fixed dose of twice-daily 300 mg in patients who are diagnosed with ovarian cancer, breast cancer, prostate cancer or pancreas cancer and has a high interpatient variability in pharmacokinetic exposure. The objective of this study was to investigate whether pharmacokinetic exposure of olaparib is related to efficacy and safety in a real-life patient' cohort. Methods: A longitudinal observational study was conducted in patients who received olaparib for metastatic ovarian cancer of whom pharmacokinetic samples were collected. A Kaplan–Meier analyses was used to explore the relationship between olaparib exposure, measured as (calculated) minimum plasma concentrations (Cmin), and efficacy, Univariate and multivariate cox-regression analyses were performed. Also, the Cmin of patients who experienced toxicity was compared with patients who did not experience any toxicity. Results: Thirty-five patients were included in the exposure-efficacy analyses, with a median olaparib Cmin of 1514 ng/mL. There was no statistical significant difference in PFS of patients below and above the median Cmin concentration of olaparib, with a hazard ratio of 1.06 (95% confidence interval: 0.46–2.45, p = 0.9)). For seven patients pharmacokinetic samples were available before toxicity occurred, these patients had a higher Cmin of olaparib in comparison with patients who had not experienced any toxicity (n = 33), but it was not statistically significant (p = 0.069). Conclusions: Our study shows that exposure of olaparib is not related to PFS. This suggests that the approved dose of olaparib yields sufficient target inhibition in the majority of patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pharmaceutical Research is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
